Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform.
Genialis has raised $13.0M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Genialis's investors include redalpine, First Star Ventures, Taiwania Capital Management Corporation, ScaleX Ventures, EASME.
Genialis is headquartered in Boston, United States.
Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform.
Genialis is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genialis — Funding & Investors." VCBacked, March 29, 2023, https://www.vcbacked.co/company/genialis. Accessed September 15, 2026.
VCBacked. (2023). Genialis — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/genialis
{{cite web |title=Genialis — Funding & Investors |url=https://www.vcbacked.co/company/genialis |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated